Safety and Efficacy of Autologous Adipose-derived Mesenchymal Stem Cells Therapy in Adults With Atrophic Scars

The purpose of this clinical trial was to evaluate the safety and efficacy of a single administration of TRTP-101 in adults with atrophic scars.

Inclusion Criteria: * Male or Female aged greater than 19 years * Acne scars graded ≥ 3 on the 5-point ASRS \[Phase 1\] * Four or more atrophic scars in the joints, genitals, perineum, and face except for the lips, eyes and nose \[Phase 2\] * Atrophic scar lesions approximately 2 cm in diameter located on the cheeks or temple on both sides of the face * A response of "dissatisfied" or worse on the Subject Acne Scar Self-Assessment Scale Exclusion Criteria: * History of cell therapy * Treatment of Dermal resurfacing, Chemical/Mechanical Peel and Skin Photorejuvenation * Treatment of Hyaluronic acid/collagen skin filler, non-permanent soft tissue filler and fat grafting * Positive for virus infection * Use of Anticoagulant therapy or NSAIDs * Thrombocytopenia or other coagulation disorder * History of keloid scars * Infectious disease or other dermatitis in the area of the atrophic scar * Use of Immunosuppressant, immunomodulating drug, anticancer drug or radiation therapy * Use of systemic steroid medication * History of hypersensitivity or severe allergic reactions (e.g., anaphylaxis, Guillain-Barre syndrome, etc.) * Use of retinoid medications